Metformin: risk-benefit profile with a focus on cancer

Bibliography

• Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer 2009;16:1103-23
   PubMed Web of Science ®Google Scholar
• Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015;350:g7607
   PubMed Web of Science ®Google Scholar
• Starup-Linde J, Karlstad O, Eriksen SA, et al. CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis. Curr Drug Saf 2013;8:296-332
   PubMedGoogle Scholar
• Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008;114:63-70
   PubMedGoogle Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60:207-21
   PubMed Web of Science ®Google Scholar
• Elks CM and Francis J. Central adiposity, systemic inflammation, and the metabolic syndrome. Curr Hypertens Rep 2010;12:99-104
   PubMed Web of Science ®Google Scholar
• Park J, Morley TS, Kim M, et al. Obesity and cancer–mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 2014;10:455-65
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-8
   PubMed Web of Science ®Google Scholar
• Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-302
   PubMed Web of Science ®Google Scholar
• Bonanni B, Puntoni M, Cazzaniga M, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012;30:2593-600
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003;163:2594-602
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010;16(6):1695-700
   PubMed Web of Science ®Google Scholar
• Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 2010;3(9):1060-5
   PubMed Web of Science ®Google Scholar
• Foretz M, Guigas B, Bertrand L, et al. Metformin: from mechanisms of action to therapies. Cell Metab 2014;20(6):953-66
   PubMed Web of Science ®Google Scholar
• Pernicova I, Korbonits M. Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014;10(3):143-56
   PubMed Web of Science ®Google Scholar
• Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12(3):159-69
   PubMed Web of Science ®Google Scholar
• Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012;2(9):778-90
   PubMed Web of Science ®Google Scholar
• Pollak M. Potential applications for biguanides in oncology. J Clin Invest 2013;123(9):3693-700
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18(16):1926-45
   PubMed Web of Science ®Google Scholar
• Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003;144(12):5179-83
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310(5754):1642-6
   PubMed Web of Science ®Google Scholar
• Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002;51(8):2420-5
   PubMed Web of Science ®Google Scholar
• Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009;9(8):563-75
   PubMed Web of Science ®Google Scholar
• Zhu Z, Jiang W, Thompson MD, et al. Metformin as an energy restriction mimetic agent for breast cancer prevention. J Carcinog 2011;10:17
   PubMedGoogle Scholar
• Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348(Pt 3):607-14
   PubMed Web of Science ®Google Scholar
• Algire C, Amrein L, Bazile M, et al. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 2011;30(10):1174-82
   PubMed Web of Science ®Google Scholar
• Hardie DG. Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology 2006;131(3):973; author reply 974-5
   PubMed Web of Science ®Google Scholar
• Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med 2015;66:17-29
   PubMed Web of Science ®Google Scholar
• Chen L, Shu Y, Liang X, et al. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci USA 2014;111(27):9983-8
   PubMed Web of Science ®Google Scholar
• Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen–induced lung tumorigenesis. Cancer Prev Res (Phila) 2010;3(9):1066-76
   PubMed Web of Science ®Google Scholar
• Smith U, Gale EA. Cancer and diabetes: are we ready for prime time? Diabetologia 2010;53:1541-34
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85
   PubMed Web of Science ®Google Scholar
• Gandini S, Guerrieri-Gonzaga A, Puntoni M, Decensi A. Metformin and breast cancer risk. J Clin Oncol 2013;31:973-4
   PubMed Web of Science ®Google Scholar
• Tsilidis K, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial. Diabetes Care 2014;37:2522-32
   PubMed Web of Science ®Google Scholar
• Quinn BJ, Kitagawa H, Memmott RM, et al. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013;24:469-80
   PubMed Web of Science ®Google Scholar
• Gandini S, Puntoni M, Heckman-Stoddard BM, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 2014;7:867-85
   PubMed Web of Science ®Google Scholar
• Thakkar B, Aronis KN, Vamvini MT, et al. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 2013;62:922-34
   PubMed Web of Science ®Google Scholar
• Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:1451-61
   PubMed Web of Science ®Google Scholar
• Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med 2014;2:57
   PubMedGoogle Scholar
• Aljada A, Mousa SA. Metformin and neoplasia: implications and indications. Pharmacol Ther 2012;133:108-15
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Pritchard KI, Ennis M, et al. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 2008;8:501-5
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Parulekar WR, Gelmon KA, et al. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst 2015;107
   Google Scholar
• Campagnoli C, Pasanisi P, Abba C, et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer 2012;12:175-82
   PubMed Web of Science ®Google Scholar
• Campagnoli C, Berrino F, Venturelli E, et al. Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer 2013;13:433-8
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
   PubMed Web of Science ®Google Scholar
• Cazzaniga M, Decensi A, Pruneri G, et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 2013;109:2792-7
   PubMed Web of Science ®Google Scholar
• Decensi A, Puntoni M, Gandini S, et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat 2014;148:81-90
   PubMed Web of Science ®Google Scholar
• Niraula S, Dowling RJ, Ennis M, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012;135:821-30
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Crew KD, Refice S, et al. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest 2014;32:150-7
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Moulder SL, Gonzalez-Angulo AM, et al. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol 2013;71:63-72
   PubMed Web of Science ®Google Scholar
• Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009;114:121-7
   PubMed Web of Science ®Google Scholar
• Nevadunsky NS, Van AA, Strickler HD, et al. Metformin use and endometrial cancer survival. Gynecol Oncol 2014;132:236-40
   PubMed Web of Science ®Google Scholar
• Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation–implications for a novel treatment strategy. Gynecol Oncol 2010;116:92-8
   PubMed Web of Science ®Google Scholar
• Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer 2014;120:2986-95
   PubMed Web of Science ®Google Scholar
• Laskov I, Drudi L, Beauchamp MC, et al. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol 2014;134:607-14
   PubMed Web of Science ®Google Scholar
• Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77
   PubMed Web of Science ®Google Scholar
• Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008;99:2136-41
   PubMed Web of Science ®Google Scholar
• Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 2010;49:662-71
   PubMed Web of Science ®Google Scholar
• Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010;3:1077-83
   PubMed Web of Science ®Google Scholar
• Kim MJ, Han JY, Shin JY, et al. Metformin-associated lactic acidosis: predisposing factors and outcome. Endocrinol Metab (Seoul) 2015;30:78-83
   Google Scholar
• Bailey CJ. Metformin–an update. Gen Pharmacol 1993;24:1299-309
   PubMedGoogle Scholar
• Wiholm BE, Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 1993;44:589-91
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010(1):CD002967
   Web of Science ®Google Scholar
• Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999;22:925-7
   PubMed Web of Science ®Google Scholar
• Duong JK, Kumar SS, Kirkpatrick CM, et al. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet 2013;52:373-84
   PubMed Web of Science ®Google Scholar
• Domecq JP, Prutsky G, Mullan RJ, et al. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab 2013;98:4646-54
   PubMed Web of Science ®Google Scholar
• Cahill DJ, O’Brien K. Polycystic ovary syndrome (PCOS): metformin. BMJ Clin Evid 2015;2015
   Google Scholar
• Nobes JP, Langley SE, Klopper T, et al. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2012;109:1495-502
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet 2009;374(9702):1677-86
   PubMed Web of Science ®Google Scholar
• Anonymous. Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care 2012;35:731-7
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008;121:149-57
   PubMed Web of Science ®Google Scholar